



China Cord Blood Corporation Announces Listing on NYSE and Pricing of Secondary Public Offering

BEIJING, China, November 19, 2009 - China Cord Blood Corporation (NYSE: CO; "the Company") today is pleased to announce the successful listing of its ordinary shares on NYSE's main board and the completion of its secondary public offering. The Company's ordinary shares are expected to begin trading on the New York Stock Exchange on November 19, 2009 under the ticker symbol "CO."

The secondary public offering of approximately 3.3 million ordinary shares at US\$6.05 per share generated gross proceeds of US\$20 million. The proceeds will be applied as working capital and seed capital for ongoing geographical expansion and potential acquisitions in China and the Asia Pacific region. The Company has granted the underwriters a 45-day over-allotment option to purchase up to an additional 495,867 ordinary shares.

"Today marks another milestone in our corporate development history," said Ms. Ting ZHENG, Chairperson and CEO of the Company. "We believe our New York Stock Exchange listing is a recognition of the Company's development over the past few years by our seasoned management team. We also believe that the listing presents us opportunities for our future expansion plan. We will use our best efforts to maintain the course of our business and at the same time seize any new opportunities in China and the Asia Pacific region as they arise."

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), is the lead bookrunner and Macquarie Capital is the joint co-bookrunner for the offering.

The Company's registration statement relating to these securities was declared effective on November 18, 2009 by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A copy of the prospectus relating to the offering may be obtained by visiting EDGAR on the SEC's Web site at <http://www.sec.gov>, or through Rodman & Renshaw LLC, Prospectus Department, 1251 Avenue of the Americas, New York, NY, 10020, telephone: 212.356.0500 or email: info@rodm.com, or through Macquarie Capitals, Prospectus Department, 125 West 55th St, 22nd Floor, New York, NY 10019, by calling 212.231.6493, by e-mailing kathleen.chung@macquarie.com.



中國臍帶血庫企業集團

China Cord Blood Corporation

About China Cord Blood Corporation

China Cord Blood Corporation is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with more than one license (i.e., Beijing and Guangdong). Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses has been issued as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.

Investor & Media Relations:

China Cord Blood Corporation

Ms. Joeling Law

Tel: (852) 3605-8180

Email: joeling.law@chinacordbloodcorp.com

Integrated Corporate Relations, Inc.

In the United States: Ashley M. Ammon or Christine Duan: 1-646-277-1200

In China: Wei-Jung Yang: 86-10-6599-7968